New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare …
…, H Bischoff, P Schraeder, T Welte, G Hoeffken - Thorax, 2009 - thorax.bmj.com
Background: The database of the German programme for quality in healthcare including
data of every hospitalised patient with community-acquired pneumonia (CAP) during a 2-year …
data of every hospitalised patient with community-acquired pneumonia (CAP) during a 2-year …
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
…, HD Orzechowski, HP Schultheiss, G Hoeffken - Chest, 2001 - Elsevier
Study objectives Primary pulmonary hypertension (PPH) is a rare disease of unknown
etiology that is characterized by a poor prognosis. This study was undertaken to investigate …
etiology that is characterized by a poor prognosis. This study was undertaken to investigate …
Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies
…, T Illmer, M Haenel, M Bornhaeuser, G Hoeffken… - Intensive care …, 2002 - Springer
Objective. To assess the outcome of intensive care unit (ICU) treatment in patients with
hematological malignancies. Design and setting. Retrospective cohort study in the medical ICU of …
hematological malignancies. Design and setting. Retrospective cohort study in the medical ICU of …
Haemoptysis due to pulmonary venous stenosis
…, M Kolditz, M Halank, G Hoeffken - European …, 2014 - Eur Respiratory Soc
Haemoptysis is a potentially life-threatening condition with the need for prompt diagnosis. In
about 10–20% of all cases the bleeding source remains unexplained with the standard …
about 10–20% of all cases the bleeding source remains unexplained with the standard …
Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension
M Halank, S Miehlke, G Hoeffken, A Schmeisser… - …, 2004 - journals.lww.com
A 47-year-old female underwent orthotopic liver transplantation (OLT) for chronic liver failure
due to alcohol and hepatitis C virus infection. There was no history of cardiorespiratory …
due to alcohol and hepatitis C virus infection. There was no history of cardiorespiratory …
Portopulmonary hypertension
M Halank, R Ewert, HJ Seyfarth, G Hoeffken - Journal of gastroenterology, 2006 - Springer
Portopulmonary hypertension (PPHT) is defined as precapillary pulmonary hypertension
accompanied by hepatic disease or portal hypertension. Pulmonary hypertension results from …
accompanied by hepatic disease or portal hypertension. Pulmonary hypertension results from …
Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension
…, B Wiedemann, M Kolditz, G Hoeffken… - Zeitschrift für …, 2011 - thieme-connect.com
Einleitung: Ambrisentan, ein selektiver Endothelinrezeptor-Antagonist, ist in vielen Ländern
zur Therapie der pulmonal-arteriellen Hypertonie zugelassen. Daten, die eine verbesserte …
zur Therapie der pulmonal-arteriellen Hypertonie zugelassen. Daten, die eine verbesserte …
Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
…, S Schiemanck, A Schmeisser, G Hoeffken - Wiener Medizinische …, 2005 - europepmc.org
Severe portopulmonary hypertension (PPHTN) is a rare complication of liver cirrhosis and
carries a poor prognosis. In the last years, intravenous (IV) epoprostenol has been suggested …
carries a poor prognosis. In the last years, intravenous (IV) epoprostenol has been suggested …
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent …
…, M Kohlhaeufl, MHU Serke, G Hoeffken… - Lung Cancer: Targets …, 2017 - Taylor & Francis
Background The aim of the study was to investigate in terms of noninferiority the efficacy and
safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus …
safety of a monochemotherapy regimen of pemetrexed plus bevacizumab (BevPem) versus …
65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with …
…, C Schumann, M Kohlhaeufl, M Serke, G Hoeffken… - 2013 - ascopubs.org
8013 Background: Pemetrexed (P) and bevacizumab (B) are efficacious drugs for treatment
of non-squamous NSCLC. In this trial the benefit of combining PB with carboplatin (C) was …
of non-squamous NSCLC. In this trial the benefit of combining PB with carboplatin (C) was …